QPPV.COM KNOWLEDGE ASSESSMENT

Durvalumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Durvalumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which operational control would most directly reduce the risk of missing delayed immune-mediated adverse reactions?
Question 2 of 10 Why can an endocrine adverse reaction be incorrectly recorded as 'recovered'?
Question 3 of 10 Which description best captures durvalumab's primary pharmacological action?
Question 4 of 10 A report describes diarrhoea during durvalumab plus chemotherapy. Which assessment best reflects the article's approach?
Question 5 of 10 Why can durvalumab produce inflammatory injury in organs that are not malignant?
Question 6 of 10 A patient develops an immune-mediated syndrome three months after the final durvalumab infusion. How should this be handled in signal detection?
Question 7 of 10 In a patient with pre-existing autoimmune disease who develops inflammation during durvalumab treatment, which information is most important for interpretation?
Question 8 of 10 A safety database classifies all reports simply as 'durvalumab exposure' without recording partner medicines or treatment phase. What is the main pharmacovigilance weakness?
Question 9 of 10 Why should durvalumab plus tremelimumab generally be analysed separately from durvalumab monotherapy?
Question 10 of 10 Which statement best describes the article's approach to unresolved multifactorial cases?

Select an answer to continue.

QPPV.com